

Updated guidance for monitoring sexual function during isotretinoin treatment (October 2025)

Monitoring side effects (including sexual function) during treatment with isotretinoin may be carried out in various ways depending on clinician/patient preference. These include verbal discussion, use of the BAD side effects proforma, or other monitoring questionnaires.

All sexually active patients should be asked at follow-up appointments whether they have any concerns about sexual function. By the third appointment this can be brief. The BAD side effects questionnaire has been amended to reflect this.